Dualitas Therapeutics
South San Francisco, US · Founded 2023 · Delaware corporation · 21 employees on LinkedIn · 7 known investors
Dualitas Therapeutics develops bispecific antibody therapies that pair a proprietary proximity engager arm with an antibody against a therapeutic target, using its DualScreen discovery engine to identify synergistic target combinations. Its pipeline targets autoimmune, allergic, and other immune and inflammatory diseases, with lead candidate DTX-102 for rheumatoid arthritis in IND-enabling studies.
Founders & leadership
FH
Forbes HuanginCo-Founder, COO & CBO
GL
Greg LazarinCo-Founder and Chief Scientific Officer
RM
Richard MurrayExecutive
KD
Karim DabbaghinChief Executive Officer, Board Member
Board
AL
MR
NW
MM
NT
TH
Thomas HudsonBoard director
Investors · 7
Qiming Venture Partners✓ verifiedBeijing · $5M – $134M
SV Health Investors✓ verifiedBoston · $1M – $20M
Versant Ventures✓ verifiedSan Francisco · $250K – $5M
AlexandriareportedPasadena
Dementia Discovery FundreportedLondonvia Neil Weir · board
Qiming HealthcarereportedBellevue
Qiming Venture Partners USAreportedCambridge
Reported raises · per SEC filings
Form D private placements$32.6M disclosed across 1 round · 2025
▶$32.6MraisedNov 2025 · 7 investors · BiotechnologyRule 506(b)
▶$32.6MraisedNov 2025 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas HudsonDirector
- Forbes HuangExecutive Officer
- Alicia LeveyDirector
- Michael RossDirector
- Greg LazarExecutive Officer
- Neil WeirDirector
- Mark McDadeDirector
- Richard MurrayExecutive Officer, Director
- Nikola TrbovicDirector
- Offering amount
- $66.6M
- Amount sold
- $32.6M
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
Immunitas Therapeutics10 shared keywordsImmunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies. The company is building on research from academic institutions including Dana Farber Cancer Institute and MIT.
Abilita Therapeutics6 shared keywordsAbilita Therapeutics is a drug discovery company focused on membrane protein targets, using its EMP (Enabled Membrane Proteins) technology based on directed evolution to create stability- and expression-enhanced protein variants for discovering and optimizing drug candidates.
Fortis Life Sciences5 shared keywordsFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.
Cabaletta Bio4 shared keywordsCabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies for patients with autoimmune diseases. Its CABA platform and lead CARTA program center on rese-cel, an investigational CD19-CAR T cell therapy being evaluated in trials across rheumatology, neurology, and dermatology.
Alloy4 shared keywordsAlloy provides drug discovery services and platform technologies across genetic medicines, TCR mimics, and cell therapies, supporting pharmaceutical partners in developing novel treatments.
Companies competing with Dualitas Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Dualitas Therapeutics do?
- Dualitas Therapeutics develops bispecific antibody therapies that pair a proprietary proximity engager arm with an antibody against a therapeutic target, using its DualScreen discovery engine to identify synergistic target combinations. Its pipeline targets autoimmune, allergic, and other immune and inflammatory diseases, with lead candidate DTX-102 for rheumatoid arthritis in IND-enabling studies.
- Who are Dualitas Therapeutics's investors?
- Dualitas Therapeutics's investors include Qiming Venture Partners, SV Health Investors, Versant Ventures, Alexandria, Dementia Discovery Fund, Qiming Healthcare, Qiming Venture Partners USA.
- How much funding has Dualitas Therapeutics raised?
- Dualitas Therapeutics has disclosed $32.6M raised across 1 round.
- Where is Dualitas Therapeutics headquartered?
- Dualitas Therapeutics is headquartered in South San Francisco, US.